Add this topic to your myFT Digest for news straight to your inbox
Annual earnings at Anglo-Swedish pharma group miss expectations but revenues rise to $45.8bn
Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen
Pascal Soriot criticises pricing agreement with UK health service
Chief executive says revenue rise will allow drugmaker to boost investment in R&D
Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings
Pharma group’s chief executive Pascal Soriot cool on need for booster shots
Pascal Soriot reveals the UK had priority access to the jab and says there is new evidence it works against variants
Bonus plan wins approval but large shareholders Aviva and Standard Life Aberdeen vote against
Investors should watch pharma group’s latest bust-up closely
Pharma group plans filing in next few weeks after controversy over previous trial results
The AstraZeneca chief is caught in the crossfire over a Covid-19 jab that could save millions
Questions mount over whether Soriot’s dash and drive, which enthral investors, have resulted in missteps
Drug company’s boss must put data concerns to rest if he is to recover from vaccine mis-steps
European officials highlight how Britain has been a big recipient of doses from EU suppliers
Commission hopes details of deal with pharma company will back its position in escalating row over delivery shortfalls
Action comes as EU holds talks with AstraZeneca over company’s cut to delivery pledges
AstraZeneca’s $39bn takeover of US bio group Alexion is a milestone moment in a busy year for M&A
Purchase of US rare disease specialist comes 6 years after pharma group saw off Pfizer takeover bid
UK drugmaker to acquire US biotech specialising in rare disease treatment
Chief executive expresses confidence despite temporary pause in trial after a participant fell ill
Drugmaker believes its potential Covid-19 vaccine ‘can be distributed in a very reasonable way’
For executives browsing DD, there are lessons to learn from the Pfizer/AstraZeneca saga
Pascal Soriot sought to deliver a research-led renaissance at AstraZeneca
Drugmaker boosted by strong performance of new treatments for cancer and heart disease
Some investors and analysts still unconvinced UK company was right to resist approach
International Edition